Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Microbiota Transplant Therapy in Primary Sclerosing Cholangitis
NCT06197308Phase 1Recruiting
- Sponsor
- University of Minnesota
- Start
- Mar 2024
- Primary completion
- Mar 2027
- Modality
- Live Biotherapeutic Products
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of MTP-101 in Primary Sclerosing Cholangitis (PSC), sponsored by University of Minnesota. Primary endpoints: Safety of Microbiota Transplant Therapy at 221 days and Feasibility of Microbiota Transplant Therapy at 221 days. Started Mar 2024; status: recruiting.
02
Drugs
MTP-101
03
Conditions
Primary Sclerosing Cholangitis (PSC)
Beyond the preview
Go deeper on NCT06197308.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06197308.